Increased Intrathecal Immune Activation in Virally Suppressed HIV-1 Infected Patients with Neurocognitive Impairment

PLoS ONE

Volumn 11, Issue 6, 2016, Pages

  Edén, Arvid ^a   Marcotte, Thomas D ^b   Heaton, Robert K ^b   Nilsson, Staffan ^c   Zetterberg, Henrik ^a,d   Fuchs, Dietmar ^e   Franklin, Donald ^b   Price, Richard W ^f   Grant, Igor ^b   Letendre, Scott L ^b   Gisslén, Magnus ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CHALMERS UNIVERSITY OF TECHNOLOGY   (Sweden)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; NEOPTERIN; NEUROFILAMENT PROTEIN; BIOLOGICAL MARKER; NEUROFILAMENT PROTEIN L;

ADULT; AGE DISTRIBUTION; ARTICLE; COGNITIVE DEFECT; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ETHNICITY; FEMALE; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; IMMUNOASSAY; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MIDDLE AGED; NERVOUS SYSTEM INFLAMMATION; NEUROLOGIC EXAMINATION; NEUROPSYCHOLOGICAL TEST; OBSERVATIONAL STUDY; YOUNG ADULT; AIDS DEMENTIA COMPLEX; CEREBROSPINAL FLUID; DRUG EFFECTS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; LONGITUDINAL STUDY;

ADULT; AIDS DEMENTIA COMPLEX; ANTI-RETROVIRAL AGENTS; BIOMARKERS; FEMALE; HIV-1; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEOPTERIN; NEUROFILAMENT PROTEINS;

EID: 84976407018     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0157160     Document Type: Article

References (31)

1. Lescure FX, Omland LH, Engsig FN, Roed C, Gerstoft J, Pialoux G, et al. Incidence and impact on mortality of severe neurocognitive disorders in persons with and without HIV infection: a Danish nationwide cohort study. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2011; 52(2):235-43. doi: 10.1093/cid/ciq041 PMID: 21288850.
2. Heaton RK, Clifford DB, Franklin DR Jr., Woods SP, Ake C, Vaida F, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology. 2010; 75 (23):2087-96. doi: 10.1212/WNL.0b013e318200d727 PMID: 21135382; PubMed Central PMCID: PMC2995535.
3. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007; 69(18):1789-99. doi: 10.1212/01.WNL. 0000287431.88658.8b PMID: 17914061.
4. Simioni S, Cavassini M, Annoni JM, Rimbault Abraham A, Bourquin I, Schiffer V, et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS (London, England). 2010; 24(9):1243-50. doi: 10.1097/QAD.0b013e3283354a7b PMID: 19996937.
5. Cysique LA, Brew BJ. Prevalence of non-confounded HIV-associated neurocognitive impairment in the context of plasma HIV RNA suppression. Journal of neurovirology. 2011; 17(2):176-83. doi: 10.1007/ s13365-011-0021-x PMID: 21416169.
6. Gisslen M, Hagberg L, Rosengren L, Brew BJ, Cinque P, Spudich S, et al. Defining and evaluating HIVrelated neurodegenerative disease and its treatment targets: a combinatorial approach to use of cerebrospinal fluid molecular biomarkers. Journal of neuroimmune pharmacology: the official journal of the Society on NeuroImmune Pharmacology. 2007; 2(1):112-9. doi: 10.1007/s11481-006-9035-1 PMID: 18040834.
7. Price RW, Epstein LG, Becker JT, Cinque P, Gisslen M, Pulliam L, et al. Biomarkers of HIV-1 CNS infection and injury. Neurology. 2007; 69(18):1781-8. doi: 10.1212/01.wnl.0000278457.55877.eb PMID: 17967994.
8. Norgren N, Rosengren L, Stigbrand T. Elevated neurofilament levels in neurological diseases. Brain Res. 2003; 987(1):25-31. PMID: 14499942.
9. Rosengren LE, Karlsson JE, Karlsson JO, Persson LI, Wikkelso C. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. Journal of neurochemistry. 1996; 67(5):2013-8. PMID: 8863508.
10. Rosengren LE, Karlsson JE, Sjogren M, Blennow K, Wallin A. Neurofilament protein levels in CSF are increased in dementia. Neurology. 1999; 52(5):1090-3. PMID: 10102440.
11. Abdulle S, Mellgren A, Brew BJ, Cinque P, Hagberg L, Price RW, et al. CSF neurofilament protein (NFL)-a marker of active HIV-related neurodegeneration. Journal of neurology. 2007. PMID: 17420923.
12. Jessen Krut J, Mellberg T, Price RW, Hagberg L, Fuchs D, Rosengren L, et al. Biomarker evidence of axonal injury in neuroasymptomatic HIV-1 patients. PLoS One. 2014; 9(2):e88591. doi: 10.1371/ journal.pone.0088591 PMID: 24523921; PubMed Central PMCID: PMC3921217.
13. Eden A, Price RW, Spudich S, Fuchs D, Hagberg L, Gisslen M. Immune activation of the central nervous system is still present after >4 years of effective highly active antiretroviral therapy. The Journal of infectious diseases. 2007; 196(12):1779-83. Epub 2008/01/15. doi: 10.1086/523648 PMID: 18190258.
14. Yilmaz A, Yiannoutsos CT, Fuchs D, Price RW, Crozier K, Hagberg L, et al. Cerebrospinal fluid neopterin decay characteristics after initiation of antiretroviral therapy. Journal of neuroinflammation. 2013; 10:62. doi: 10.1186/1742-2094-10-62 PMID: 23664008; PubMed Central PMCID: PMC3657550.
15. Gisslen M, Price RW, Nilsson S. The definition of HIV-associated neurocognitive disorders: are we overestimating the real prevalence? BMC infectious diseases. 2011; 11:356. doi: 10.1186/1471-2334-11-356 PMID: 22204557; PubMed Central PMCID: PMC3260107.
16. Torti C, Foca E, Cesana BM, Lescure FX. Asymptomatic neurocognitive disorders in patients infected by HIV: fact or fiction? BMC medicine. 2011; 9:138. doi: 10.1186/1741-7015-9-138 PMID: 22204606; PubMed Central PMCID: PMC3273440.
17. Grant I, Franklin DR Jr., Deutsch R, Woods SP, Vaida F, Ellis RJ, et al. Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline. Neurology. 2014; 82(23):2055-62. doi: 10.1212/WNL.0000000000000492 PMID: 24814848; PubMed Central PMCID: PMC4118496.
18. Blackstone K, Moore DJ, Franklin DR, Clifford DB, Collier AC, Marra CM, et al. Defining neurocognitive impairment in HIV: deficit scores versus clinical ratings. The Clinical neuropsychologist. 2012; 26 (6):894-908. doi: 10.1080/13854046.2012.694479 PMID: 22708483; PubMed Central PMCID: PMC3848322.
19. Carey CL, Woods SP, Gonzalez R, Conover E, Marcotte TD, Grant I, et al. Predictive validity of global deficit scores in detecting neuropsychological impairment in HIV infection. Journal of clinical and experimental neuropsychology. 2004; 26(3):307-19. doi: 10.1080/13803390490510031 PMID: 15512922.
20. Cysique LA, Franklin D Jr., Abramson I, Ellis RJ, Letendre S, Collier A, et al. Normative data and validation of a regression based summary score for assessing meaningful neuropsychological change. Journal of clinical and experimental neuropsychology. 2011; 33(5):505-22. doi: 10.1080/13803395.2010. 535504 PMID: 21391011; PubMed Central PMCID: PMC3151558.
21. Heaton RK, Franklin DR Jr., Deutsch R, Letendre SL, Ellis RJ, Casaletto K, et al. Neurocognitive change in the era of HIV combination antiretroviral therapy: A longitudinal CHARTER Study. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2014. doi: 10. 1093/cid/ciu862 PMID: 25362201.
22. Hagberg L, Cinque P, Gisslen M, Brew BJ, Spudich S, Bestetti A, et al. Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection. AIDS research and therapy. 2010; 7:15. doi: 10.1186/1742-6405-7-15 PMID: 20525234; PubMed Central PMCID: PMC2890504.
23. Krut JJ, Zetterberg H, Blennow K, Cinque P, Hagberg L, Price RW, et al. Cerebrospinal fluid Alzheimer's biomarker profiles in CNS infections. Journal of neurology. 2013; 260(2):620-6. doi: 10.1007/ s00415-012-6688-y PMID: 23052602.
24. Brew BJ, Dunbar N, Pemberton L, Kaldor J. Predictive markers of AIDS dementia complex: CD4 cell count and cerebrospinal fluid concentrations of beta 2-microglobulin and neopterin. The Journal of infectious diseases. 1996; 174(2):294-8. PMID: 8699058.
25. Gelman BB, Chen T, Lisinicchia JG, Soukup VM, Carmical JR, Starkey JM, et al. The National NeuroAIDS Tissue Consortium brain gene array: two types of HIV-associated neurocognitive impairment. PLoS One. 2012; 7(9):e46178. doi: 10.1371/journal.pone.0046178 PMID: 23049970; PubMed Central PMCID: PMC3458860.
26. Mellgren A, Price RW, Hagberg L, Rosengren L, Brew BJ, Gisslen M. Antiretroviral treatment reduces increased CSF neurofilament protein (NFL) in HIV-1 infection. Neurology. 2007; 69(15):1536-41. doi: 10.1212/01.wnl.0000277635.05973.55 PMID: 17923616.
27. Peterson J, Gisslen M, Zetterberg H, Fuchs D, Shacklett BL, Hagberg L, et al. Cerebrospinal fluid (CSF) neuronal biomarkers across the spectrum of HIV infection: hierarchy of injury and detection. PLoS One. 2014; 9(12):e116081. doi: 10.1371/journal.pone.0116081 PMID: 25541953; PubMed Central PMCID: PMC4277428.
28. Bogner JR, Junge-Hulsing B, Kronawitter U, Sadri I, Matuschke A, Goebel FD. Expansion of neopterin and beta 2-microglobulin in cerebrospinal fluid reaches maximum levels early and late in the course of human immunodeficiency virus infection. The Clinical investigator. 1992; 70(8):665-9. PMID: 1392442.
29. Yilmaz A, Price RW, Spudich S, Fuchs D, Hagberg L, Gisslen M. Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy. Journal of acquired immune deficiency syndromes (1999). 2008; 47(2):168-73. doi: 10.1097/QAI.0b013e31815ace97 PMID: 17971711; PubMed Central PMCID: PMC2628632.
30. Dahl V, Peterson J, Fuchs D, Gisslen M, Palmer S, Price RW. Low levels of HIV-1 RNA detected in the cerebrospinal fluid after up to 10 years of suppressive therapy are associated with local immune activation. AIDS (London, England). 2014; 28(15):2251-8. doi: 10.1097/QAD.0000000000000400 PMID: 25022595.
31. Sattler FR, He J, Letendre S, Wilson C, Sanders C, Heaton R, et al. Abdominal obesity contributes to neurocognitive impairment in HIV-infected patients with increased inflammation and immune activation. Journal of acquired immune deficiency syndromes (1999). 2015; 68(3):281-8. doi: 10.1097/QAI. 0000000000000458 PMID: 25469522; PubMed Central PMCID: PMC4551458.